Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, says it can reduce cell line development timelines with its new Apollo X Advanced Mammalian Expression System.   The introduction of new single step cloning technology, in combination with the new Apollo X host cell line has allowed development timelines to be significantly reduced. The Apollo X Ad...